Observations with a combined oral contraceptive (Rigevidon) containing minimum oestrogen dose.
D000293:Adolescent; D000328:Adult; D003276:Contraceptives, Oral / Q000009:adverse effects*; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects*; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects; D004967:Estrogens / Q000008:administration & dosage*; D004997:Ethinyl Estradiol / Q000009:adverse effects*; D019304:Ethinyl Estradiol-Norgestrel Combination; D005040:Ethynodiol Diacetate / Q000009:adverse effects; D005260:Female; D006801:Humans; D008656:Mestranol / Q000009:adverse effects; D009644:Norgestrel / Q000009:adverse effects*; D011247:Pregnancy
D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D003278:Contraceptives, Oral, Hormonal; D004967:Estrogens; D009644:Norgestrel; D004997:Ethinyl Estradiol; D005040:Ethynodiol Diacetate; D019304:Ethinyl Estradiol-Norgestrel Combination; C018467:Bisecurin I; D008656:Mestranol